Could distal MSH2 upstream deletions cause HNPCC? … another cancer susceptibility factor. John Taylor CMGS Spring Conference 2009.

Slides:



Advertisements
Similar presentations
Colon Cancer The life time risk of developing Colon Cancer in the United States in one in sixteen. This means 144,000 new cases a year accounting for.
Advertisements

Chapter 19 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
This short questionnaire will help to determine whether there may be a gene in your family connected to an increased risk of the development of bowel.
A review of the Wilson disease service over the past 15 years Miranda Durkie Sheffield Diagnostic Genetics Service
CMGS LS FAP MAP Training Day, 30/11/2009 Colorectal Cancer BP Training Day Ian M Frayling Consultant Genetic Pathologist Director, Laboratory Genetics.
Hereditary GI Cancer-a Primer for Medical Oncologists
MLH1 c.1852_1853delinsGC (aka c.1852_1853AA>GC, Lys618Ala)  Leeds – found in 4 out of ~400 patients  DMuDB – entered Birmingham (x6), Leeds (x1), Dundee.
HNPCC Case report Referral Bowel Cancer aged 49 and a possible family History of HNPCC.
Clinical background: Patient RM, YoB 1966 Her family were originally referred because of a history of breast and ovarian cancer. BRCA testing found a missense.
Suggestions for PMS2 best practice Jenny Simmonds
HNPCC and FAP are both associated with familial colon cancer but differ in many aspects. Describe the similarities and differences between these conditions.
Development of a molecular genetic diagnostic service for X-linked ichthyosis, with emphasis on carrier detection Eleanor Reavey West of Scotland Regional.
Familial Colorectal Cancers Francis M. Giardiello, M.D. The Johns Hopkins University.
Comprehensive IHC Screening for Lynch Syndrome: What You Need to Know Andrea Lewis, MS, CGC January 14, 2010.
Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:
HENRY T. LYNCH, MD JANE F. LYNCH, BSN Creighton University
MLH 1 and Hereditary Nonpolyposis Colorectal Cancer
BMP Receptor 1 : Juvenile Polyposis (Colon Cancer) Cecily Johnson Biology 169 March 24, 2005.
MSH2 and Human Nonpolyposis Colon Cancer Yael Aschner.
HNPCC and MLH1 Qi Peng Cancer Biology March 30 th, 2006.
ZAFIA ANKLESARIA Role of BMPR1A in Juvenile Polyposis Syndrome Biology 169.
Molecular Pathology – Cell cycle Dr. Leonard Da Silva Senior Lecturer Molecular & Cellular Pathology.
Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.
The Hunt for Chromosomal Determinants of Maleness— A gene mapping story……. The Hunt for Chromosomal Determinants of Maleness— A gene mapping story…….
Tumor Supressor Gene Non-functional TSG Mutations increasing risk of cancer “Loss of function” mutation Proto-oncogene Oncogene (Hyperactive or unregulated.
Building a Model of Tumorigenesis: A small group activity for a Cancer Biology/Cell Biology course L. K. Wright Supplemental File : Multistep Tumorigenesis.
Large-Scale Copy Number Polymorphism in the Human Genome J. Sebat et al. Science, 305:525 Luana Ávila MedG 505 Feb. 24 th /24.
Dr Gihan E-H Gawish, MSc, PhD Molecular Biology and Clinical Biochemistry KSU Cytogenetics Understanding the Disease Progression Process, Classical and.
Expanded PLA2G6 Copy Number Variant Analysis in Patients with Infantile Neuroaxonal Dystrophy (INAD) Danielle Crompton, P. K. Rehal, L. MacPherson, K.
Investigating the use of Multiple Displacement Amplification (MDA) to amplify nanogram quantities of DNA to use for downstream mutation screening by sequencing.
MLH1 & its role in Lynch Syndrome and sporadic colorectal cancers By Annie Jin.
Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.
Apparent homozygous deletion identified in Alström syndrome patient Elizabeth Perrott West Midlands Regional Genetics Laboratory.
The Biology and Genetic Base of Cancer. 2 (Mutation)
Development: differentiating cells to become an organism.
Eukaryotic Genomes 15 November, 2002 Text Chapter 19.
Molecular characterization of the DYX1C1 gene and its application as a cancer biomarker Heui-Soo Kim 1, Yun-Ji Kim 1, Jae-Won Huh 1,2, Dae-Soo Kim 1,3,
Telomerase, Immortalization and Cancer Eric Bankaitis Cancer Bio 169 March 9, 2006 Fig.[9]
1 LYNCH SYNDROME EPCAM FAMILY WITH PREDOMINANT COLORECTAL CANCER HENRY T. LYNCH, MD; STEPHEN N. THIBODEAU, PHD; CARRIE SNYDER, MSN, RN, APNG; JENNIFER.
Eukaryotic Genomes 11 November, 2005 Text Chapter 19.
MLH1: Hereditary non- polyposis colon cancer (HNPCC) By: Alison Edge.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Identification of a Novel TP53 Cancer Susceptibility.
Homework #2 is due 10/18 Bonus #1 is due 10/25. The order of Hox genes parallels the order of body parts in which they are expressed Fig
MLH1 and HNPCC March 29, 2005 Tammy Jernigan
Frances Bond West Midlands Regional Genetics Laboratory 12/04/10
Germline and Somatic Mutations of the STK11/LKB1 Peutz-Jeghers Gene in Pancreatic and Biliary Cancers  Gloria H. Su, Ralph H. Hruban, Ravi K. Bansal,
Imprinting-Mutation Mechanisms in Prader-Willi Syndrome
Myopodin, a Synaptopodin Homologue, Is Frequently Deleted in Invasive Prostate Cancers  Fan Lin, Yan-Ping Yu, Jeff Woods, Kathleen Cieply, Bill Gooding,
Warm Up for 12/1/15 You get ____ chromosomes from your mom and ___ chromosomes from your dad to give you a total of ____ chromosomes. Autosomes include.
Identification of EpCAM as the Gene for Congenital Tufting Enteropathy
Novel Functional Single Nucleotide Polymorphisms in the Latent Transforming Growth Factor-β Binding Protein-1L Promoter  Tomomi Higashi, Satoru Kyo, Masaki.
Genomic Instability and Cancer
Colorectal cancer : Three pathways
The Role of MSH2 in Hereditary Non-Polyposis Colon Cancer
Genetic testing for high-risk colon cancer patients1
Volume 117, Issue 2, Pages (August 1999)
Intrinsic and acquired trastuzumab resistance.
Sequencing of t(2;7) Translocations Reveals a Consistent Breakpoint Linking CDK6 to the IGK Locus in Indolent B-Cell Neoplasia  Edward P.K. Parker, Reiner.
BMP Receptor 1a and Juvenile Polyposis Syndrome
Noralane M Lindor  Clinical Gastroenterology and Hepatology 
T. Ohta, K. Buiting, H. Kokkonen, S. McCandless, S. Heeger, H
Mutations in a Novel Gene with Transmembrane Domains Underlie Usher Syndrome Type 3  Tarja Joensuu, Riikka Hämäläinen, Bo Yuan, Cheryl Johnson, Saara.
The Morphogenetic Code and Colon Cancer Development
Barbara Jung, Jonas J. Staudacher, Daniel Beauchamp  Gastroenterology 
Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer  Ramprasath Venkatachalam  Gastroenterology 
Colonic polyps and tumors
Characterization of a Recurrent Novel Large Duplication in the Cystic Fibrosis Transmembrane Conductance Regulator Gene  Feras M. Hantash, Joy B. Redman,
The Tumor-Necrosis-Factor Receptor–Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence.
Contiguous Deletion of the X-Linked Adrenoleukodystrophy Gene (ABCD1) and DXS1357E: A Novel Neonatal Phenotype Similar to Peroxisomal Biogenesis Disorders 
Presentation transcript:

Could distal MSH2 upstream deletions cause HNPCC? … another cancer susceptibility factor. John Taylor CMGS Spring Conference 2009

Hereditary non-polyposis colorectal cancer. HNPCC (Lynch syndrome) Mutations in the Mismatch repair (MMR) pathway.  Four genes  MLH1  PMS2  MSH2  MSH6 Colorectal cancer (right hand side).  Extra-colonic carcinomas (MSH2 & MSH6).  Endometrial  Stomach  Small bowel  Hepatobiliary tract

Hereditary non-polyposis colorectal cancer. MSH6MSH2 A T U G G C A T T G C

Patient referrals. “A”“Z”Patient Initials IHC analysisLoss of MSH2 MSIMSI-H Other affected family members Mother [“B”]None Previous molecular analysis MSH2 / MLH1 –ve mutation screen

Interrogation of the MSH6 gene. Patients “A” and “Z” were referred for an MSH6 mutation screen.  Direct sequence analysis.  MLPA analysis (MRC Holland kit P008) Both patients were normal and had no mutations other than neutral polymorphisms in MSH6 and no deletions were identified. However, the MLPA kit contained additional probes:  TACSTD1 exon 7  TACSTD1 exon 9 A B C Figure 3.1. Multiplex ligation-dependant probe amplification (MLPA) electropherogram traces for; A) a normal control; B) patient “A”; C) patient “Z”. SNPs excluded by direct sequence analysis of exon 9

TACSTD1 exon 9 deletion. This region chromosome 2p is very repetitive; Alu-rich sequence. Previous studies have shown deletions within the coding region of MSH2 can extend into the promoter region and as far as the TACSTD1 gene. Francoise Charbonnier et al., (2005) Human Mutation 26(3), Recombination between Alu elements have also been shown (ex1-ex6). Anja Wager et al., (2003) Am J. Hum. Genet.72: Could the apparent deletion in TACSTD1 ex9 extend into the promoter of MSH2?

QF-PCR analysis. Charbonnier et al., (2002) Cancer Research 62: Map of the exons within chromosome 2 (positions 47,483, ,642,954) *promoter region as determined by Iwahashi Y et al.,(1998) Gene 213:141– kb MSH2 exon 3 MSH2 start kb kb MSH2 exon 1 TACSTD1 exon 9 TACSTD1 exon 8 P1 P2 P3 MSH2 exon 2 PH1 PZ P4 P5Ex 7 Ex 1 Ex 3 P6 MSH2 promoter ~4.4Kb* TACSTD1 exon 7 Msh2 Ex 6 Msh2 Ex 16 Msh2 Ex 6 Normal “A” “Z”

QF-PCR analysis. Charbonnier et al., cancer Research 62, Map of the exons within chromosome 2 (positions 47,483, ,642,954) *promoter region as determined by Iwahashi Y et al.,(1998) Gene 213:141– kb MSH2 exon 3 MSH2 start kb kb MSH2 exon 1 TACSTD1 exon 9 TACSTD1 exon 8 P1 P2 P3 MSH2 exon 2 PH1 PZ P4 P5Ex 7 Ex 1 Ex 3 P6 MSH2 promoter ~4.4Kb* TACSTD1 exon 7 Msh2 Ex 6 Msh2 Ex 16 Msh2 Ex 6 “A” “B” “Z”

Long-Range PCR. Standard curve using λ DNA ladder KB NCZAB-VE λ The primer set for MSH2P4 is 10 kb upstream of MSH2

What was the significance of these deletions? Long-range PCR excluded the possibility of chromosomal rearrangements and inversions within this region. All deletions are in excess of 10kb upstream of the MSH2 transcriptional start and are unlikely to affect transcription factor binding sites. Farré et al., (2007) Genome Biology 8:R140. The deletion co-segregates with the apparent loss of MSH2 by IHC (although only through one generation) Two additional patients from the Salisbury lab were tested and found to have the same deletion size and haplotype (two markers [D2S123 and D2S391]) as patients “A” and “B”. Findings up until Nov 2008

Recent publications kb MSH2 exon 3 MSH2 start kb kb MSH2 exon 1 TACSTD1 exon 9 TACSTD1 exon 8 P1 P2 P3 MSH2 exon 2 PH1 PZ P4 P5Ex 7 Ex 1 Ex 3 P6 MSH2 promoter ~4.4Kb* TACSTD1 exon 7 1.Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Ligtenberg et al., Nat. Gen. Vol 41 (1) p Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to lynch syndrome. Kovacs et al., Hum. Mut. Vol. 30, No. 2, 197–203. Publications since January 2009: Both publications agree that the removal of the TACSTD1 polyadenylation signal in exon 9 resulted in the continuation of the transcriptional elongation from the TACSTD1 gene into the downstream MSH2 gene.

Concluding remarks. What started of as a coincidental finding appears to a novel cancer susceptibility factor associated with HNPCC. Upstream deletions within exon 9 of the TACSTD1 gene can lead to the loss of MSH2 in colonic adenoma tissue, detectable by IHC, and is consistent with a diagnosis of HNPCC. It is unlikely that these deletions alter the expression on MSH2 directly (i.e. removing transcription factor binding sites), but rather indirectly by transcriptional silencing due to the strength of the TACSTD1 promoter and loss of the polyadenylation signal. One further consideration:  Could this type of mutation influence the spectrum of cancers associated with MSH2 traditionally associated with extra-colonic carcinomas?

Acknowledgements. Jennie Bell Fiona Macdonald Matthew Smith Dave Bunyan (Salisbury)

Appendix 1 – Functions of TACSTD1/EpCAM Trzpis et al., (2007) The American Journal of Pathology, Vol. 171, p

Appendix 2 – Signalling and CC-ICs The morphological unit of the small intestine is the crypt–villus, lined with Paneth cells at the bottom of the crypt (yellow). Stem cells are located on top of Paneth cells (violet) and also give rise to transit amplifying (TA) precursors in the remainder of the crypt. TA cells undergo terminal differentiation under the influence of gradients of morphogenetic ligands while migrating to the villus, before being shed in the lumen. Right: a schematic description of the differentiation pathways in the gut epithelium. BMP, bone morphogeneic protein; TGFβ, transforming growth factor β. Ricci-Vitiani et al., Gut (2008);57;

Appendix 3 - Congenital Tufting Enteropathy (CTE) Schematic of duodenal mucosa showing histology of (A) normal intestinal villus and (B) congenital tufting enteropathy villus with crowded epithelial cells forming tufts, villus atrophy. (C) H&E-stained duodenal tissue (original magnification, 20x )from affected patients (P1 and P2) exhibiting tufting and crowding of epithelial cells. Congenital tufting enteropathy (CTE) is a rare autosomal recessive diarrheal disorder presenting in the neonatal period. CTE is characterized by intestinal epithelial cell dysplasia leading to severe malabsorption and significant morbidity and mortality. Taken from Sivagnanam et al., Gastroenterology (2008);135:429–437 Patients P1 and P2 were found to be homozygous G>A substitution in the affected patients at the donor splice site (c.491+1G>A) of exon 4 of TACSDT1/EpCAM EpCAM function may be important for the development of the crypt villus axis, where epithelial cells originate from stem cells in the crypt and migrate distally to the tip of the villus prior to shedding.